DNA Methylation and Arsenic-associated Urothelial Carcinoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators previously pointed out the significant association between urinary arsenic profiles and urothelial carcinoma (UC) risk through a 12-year follow-up study. Further, the investigators observed the increased UC risk in people with lower plasma folate and higher homocysteine than those with higher plasma folate and lower homocysteine in 2010. S-adenosylmethionine (SAM) is one factor included in one-carbon metabolism pathway and is the main donor of methyl group in cells. The ratio of SAM and its metabolite S-adenosylhomocysteine (SAH) not only reflected the intake level of dietary folate but also demonstrated the extent of global DNA methylation. These factors might play important roles in UC carcinogenesis. The investigators would expect to take three years to explore the interactions among global DNA methylation, one-carbon metabolic pathway factors, urinary arsenic profiles, the polymorphisms and haplotype of Glycine N-methyltransferase (GNMT) and UC. In the first year, the investigators would measure the levels of plasma folate, homocysteine, SAM and SAH and evaluate the associations between these factors and UC risk. In the second year, the investigators would set up the method of immunohistochemistry stain and compare the differences between the global DNA methylation from bladder tissues and blood. In the last year, this investigators would analyze the GNMT gene polymorphism and haplotype variation. At the same time, the investigators would explore the impact of GNMT genetic variation and global DNA methylation on UC risk. Based on the results from our research, the investigators might propose that the decreased ratio of SAM/SAH resulted in UC risk increased. This mechanism might be through the changed levels of urinary arsenic profiles and global DNA methylation.
| Condition |
|---|
|
Urothelial Carcinoma |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | Comparison of DNA Methylation Between Urothelial Carcinoma and Healthy Controls |
- urothelial carcinoma [ Time Frame: up to three years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 600 |
| Study Start Date: | May 2011 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
urothelial carcinoma
Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
|
|
Healthy controls group
Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
|
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
This is a hosital-based case-control study. Patients with urothelial carcinoma are recruited by pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists. Healthy controls without evidence of UC or any other malignancy were recurited including those receiving adult health examinations at China Medical University Hospital.
Inclusion Criteria:
- Clinical diagnosis of urothelial carcinoma
- The voluntary of participating the study
Exclusion Criteria:
- Age smaller than 20 years
- Pregnant women
- Not willing to participate the study because of their personal reasons
Contacts and Locations| Contact: Chao-Hsiang Chang, PhD | 886-4-22052121 ext 4439 | urology8395@yahoo.com.tw |
| Taiwan | |
| Department of Urology, China Medical University Hospital | Recruiting |
| Taichung, Taiwan, 404 | |
| Contact: Chao-Hsiang Chuang, PhD 886-4-22052121 ext 4439 urology8395@yahoo.com.tw | |
| Principal Investigator: Chi-Jung Chung, PhD | |
| Principal Investigator: | Chi-Jung Chung, PhD | Department of Health risk Management, China Medical University |
More Information
No publications provided
| Responsible Party: | Chi-Jung Chung and Chao-Hsian Chang, Department of Urology |
| ClinicalTrials.gov Identifier: | NCT01360723 History of Changes |
| Other Study ID Numbers: | DMR100-IRB-080 |
| Study First Received: | May 24, 2011 |
| Last Updated: | May 26, 2011 |
| Health Authority: | Taiwan: Department of Health |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Transitional Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |
ClinicalTrials.gov processed this record on May 19, 2013